In this video, Motley Fool health care analyst David Williamson discusses what investors should look for in Vertex's upcoming earnings report and what the biotech has in store for 2013, including a collaboration with Johnson & Johnson.
Foolish Preview: Vertex Earnings
Taking a look at the biotech's soon-to-be-reported 4th quarter.
By Dave Williamson – Jan 29, 2013 at 3:21PM EST
Read Next
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Stocks Mentioned
Vertex Pharmaceuticals
NASDAQ: VRTX
$492.96
(-1.24%)-$6.21
Johnson & Johnson
NYSE: JNJ
$242.91
(-0.33%)-$0.81
Gilead Sciences
NASDAQ: GILD
$148.10
(-0.31%)-$0.46
GSK
NYSE: GSK
$55.13
(-0.34%)-$0.19
AbbVie
NYSE: ABBV
$226.90
(-0.05%)-$0.11
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.